Search research articles
Contact Us
Filters
Showing results (51-60 of 144) with videos related to
Page
of 15
Sort By:
American Journal of Clinical Oncology
|
August 1, 1991
Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08
J D Cox, T F Pajak, A Herskovic, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 15, 1993
A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07
R W Byhardt, T F Pajak, B Emami, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 20, 1993
The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol
R W Byhardt, L Martin, T F Pajak, et al.
Cancer
|
November 1, 1981
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B
F Cavalli, W F Jungi, N I Nissen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1990
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11
J D Cox, N Azarnia, R W Byhardt, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 1, 1989
A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04)
D J Lee, T F Pajak, J Stetz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 1, 1987
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck
J Fazekas, T F Pajak, T Wasserman, et al.
Annals of Surgery
|
November 1, 1994
Evaluation of preoperative radiation therapy in operable colorectal cancer
W T Sause, T F Pajak, R D Noyes, et al.
Medical and Pediatric Oncology
|
January 1, 1978
Combination chemotherapy of non-Hodgkin lymphoma
R J Forcier, O R McIntyre, N I Nissen, et al.
Medical and Pediatric Oncology
|
January 1, 1982
Severe neurotoxicity with methyl G: CALGB experience
M B Spaulding, S S Barron, R L Comis, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 144) with videos related to
Sort By:
Page
of 15
American Journal of Clinical Oncology
|
August 1, 1991
Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08
J D Cox, T F Pajak, A Herskovic, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 15, 1993
A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07
R W Byhardt, T F Pajak, B Emami, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 20, 1993
The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol
R W Byhardt, L Martin, T F Pajak, et al.
Cancer
|
November 1, 1981
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B
F Cavalli, W F Jungi, N I Nissen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1990
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11
J D Cox, N Azarnia, R W Byhardt, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 1, 1989
A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04)
D J Lee, T F Pajak, J Stetz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 1, 1987
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck
J Fazekas, T F Pajak, T Wasserman, et al.
Annals of Surgery
|
November 1, 1994
Evaluation of preoperative radiation therapy in operable colorectal cancer
W T Sause, T F Pajak, R D Noyes, et al.
Medical and Pediatric Oncology
|
January 1, 1978
Combination chemotherapy of non-Hodgkin lymphoma
R J Forcier, O R McIntyre, N I Nissen, et al.
Medical and Pediatric Oncology
|
January 1, 1982
Severe neurotoxicity with methyl G: CALGB experience
M B Spaulding, S S Barron, R L Comis, et al.
Page
of 15